EuroscreenFAST is the CRO unit of Epics Therapeutics S.A. offering screening and assay development services with a particular focus on G protein coupled receptors (GPCR).
Founded in 1994 as a spin-off of the Université Libre de Bruxelles (ULB), Euroscreen S.A. has been dedicated since to advancing GPCR-targeted drug discovery. The company has a dual business-model with the EuroscreenFast CRO Unit and the Drug Discovery Unit conducting internal research programs.
EuroscreenFast is a trusted provider of assay development and screening services as recognized by over 300 customers worldwide, from small biotech to large pharmaceutical companies, as well as cosmetic/nutraceuticals and academic institutions.
Euroscreen S.A. was rebranded Ogeda S.A. in 2016, and was acquired by Astellas Pharma in 2017 after its first clinical candidate Fezolinetant generated positive data in a Phase IIa clinical trial in menopausal hot flashes.
In January 2019, Ogeda transferred part of its assets, including research programs and the EuroscreenFast business unit to Epics Therapeutics S.A.